Allergic burden and the risk of venous thromboembolism.

1 De Boeck K, Kent L, Davies J, et al. CFTR biomarkers: time for promotion to surrogate end-point? Eur Respir J 2013; 41: 203–216. 2 Durmowicz AG, Witzmann KA, Rosebraugh CJ, et al. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 2013; 143: 14–18. 3 Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663–1672. 4 Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363: 1991–2003. 5 Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67: 12–18. 6 Suri R, Metcalfe C, Wallis C, et al. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respir Med 2007; 101: 254–260. 7 Brody AS, Sucharew H, Campbell JD, et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1128–1132.